Pharmaceuticals, Biotechnology and Life Sciences
The American Brain Tumor Association (ABTA) has elected four new members to its Board of Directors in January, to bring the number of directors to thirteen.
AstraZeneca has entered into an agreement with TerSera Therapeutics for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada, an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.
Risperdal lawsuits involving Johnson & Johnson medication to gynecomastia, (male breast growth) and other side effects allegedly associated with use of the atypical antipsychotic medication continue to move forward in the Philadelphia Court of Common Pleas, said Bernstein Liebhard LLP is a New York-based law firm representing the victims of defective drugs and medical devices in USA.
AbbVie plans to it increase its earnings per share and elevates the market value of the remaining shares, as it has authorized a $5 billion increase to AbbVie’s existing stock repurchase program.
Takeda and TiGenix have presented new data from the Phase 3 ADMIRE-CD clinical trial of treatment refractory complex perianal fistulas in patients with Crohn’s disease at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO).
AbbVie, the global research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories has declared a quarterly cash dividend of $0.64 per share.
Alexion Pharmaceuticals’s revenues for 2016 increased 18% compared to the previous year, bringing $3.1 billion, and that’s with a negative impact of foreign currency of 3% or $74 million, bringing net income of $399 million, way up from $144 million last year.
Boston-based pharmaceutical company Rhythm has secured $41 million through mezzanine financing round to funds its melanocortin-4 receptor for the phase 3 study.
Premier Veterinary Group’s subsidiary, Premier Vet Alliance (“PVA”), has signed the third co-operation agreement since its entry to the US market in May 2016.
The U.S. Food and Drug Administration (FDA) has approved Valeant Pharmaceuticals’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.